Founded in late 1997, NewBiotics is focused on developing new therapeutics designed to exploit common enzyme-mediated drug-resistance mechanisms in cancer and infectious disease. In addition to its ECTA technology, the company is developing its patented Double-Minute chromosome technology for inducing the elimination of cancer-specific chromosomes.
